CG Oncology (CGON) Enterprise Value (2023 - 2026)

CG Oncology's Enterprise Value history runs 4 years deep, the most recent figure standing at -$1.1 billion for Q1 2026.

• Quarterly Enterprise Value fell 56.33% year-over-year to -$1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 billion (down 56.33% YoY) and the FY2025 annual result came in at -$742.2 million, changed 0.02% from the prior year.
• Enterprise Value was -$1.1 billion for Q1 2026 at CG Oncology, down from -$742.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$187.7 million in Q4 2023 and bottomed at -$1.1 billion in Q1 2026.
• A 4-year average of -$643.8 million and a median of -$670.7 million in 2025 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value sank 295.37% — and 2025, when it fell 0.02%.
• CG Oncology's Enterprise Value stood at -$187.7 million in 2023, then sank by 295.37% to -$742.0 million in 2024, then retreated by 0.02% to -$742.2 million in 2025, then plunged by 45.02% to -$1.1 billion in 2026.
• Business Quant data shows CGON's Enterprise Value at -$1.1 billion in Q1 2026, -$742.2 million in Q4 2025, and -$680.3 million in Q3 2025.